Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Preclinical and Early Clinical Results Indicate a Role for the Oral p300/CBP Inhibitor Inobrodib (CCS1477) in T-Cell Lymphoma

Victoria Campbell, Harriet Walter, Adam Gibb, Andrew S. Davies, Nagah Elmusharaf, Neil Pegg, Will Henry West, Tomasz Knurowski, Kris Frese, Debbie Haynes, Karen Clegg, Tim Somervaille

Blood (2023) 142 (Supplement 1): 5795.

https://doi.org/10.1182/blood-2023-187378

Published: 2023

Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Who Received Third Line Therapy at the Christie NHS Foundation Trust in the UK

Kim Linton, Cristina Julian, Adam Gibb, Ellie White, Emma-Frances Armstrong, Yun Li, Yutong Liu, Ashwini Shewade, John Radford

Blood (2021) 138 (Supplement 1): 5011.

https://doi.org/10.1182/blood-2021-148490

Published: 2021

Journal Articles

Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common

Stephen Booth, MA,MBBChir,MRCP,FRCPath, Hannah Plaschkes, Amy A Kirkwood, Adam Gibb, MBBS, Patrick Horgan, Joanna M Oladipo, Joseph Andrew Browning, DPhil,BMBCh, Usman Khan, John Willan, Julia Wolf, Arief Gunawan, MBBS, BSc, MRCP, Paul A Fields, MD PhD, Kim Linton, MBChB PhD, Claire Higham, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Jaimal Kothari, Catherine Hildyard, Toby A. Eyre

Blood (2019) 134 (Supplement_1): 1615.

https://doi.org/10.1182/blood-2019-127374

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD

Blood (2019) 134 (Supplement_1): 2917.

https://doi.org/10.1182/blood-2019-123664

Published: 2019

Journal Articles

Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012

Blood (2015) 126 (23): 1499.

https://doi.org/10.1182/blood.V126.23.1499.1499

Published: 2015

NARROW

Preclinical and Early Clinical Results Indicate a Role for the Oral p300/CBP Inhibitor Inobrodib (CCS1477) in T-Cell Lymphoma

Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Who Received Third Line Therapy at the Christie NHS Foundation Trust in the UK

Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012

Email alerts

ASH Publications

American Society of Hematology

Preclinical and Early Clinical Results Indicate a Role for the Oral p300/CBP Inhibitor Inobrodib (CCS1477) in T-Cell Lymphoma

Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Who Received Third Line Therapy at the Christie NHS Foundation Trust in the UK

Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only